3D InSight™ Human Liver Disease Platform will be used to screen effects of Akero lead program AKR-001 on underlying metabolic and fibrotic drivers of NAFLD and NASH. SCHLIEREN, Switzerland and SAN FRANCISCO, Oct. 3, 2019 /PRNewswire/ -- Akero Therapeutics and InSphero AG today announced that Akero

SAN FRANCISCO , Sept. 4, 2019 /PRNewswire/ --  Akero Therapeutics, Inc.  (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that members of the

-- Advanced AKR-001 into Phase 2a BALANCED clinical study in NASH -- -- Raised $98.4 million in aggregate net proceeds from Initial Public Offering -- SAN FRANCISCO , Aug. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc.  (Nasdaq: AKRO), a clinical-stage biotechnology company developing

SAN FRANCISCO , July 2, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the dosing of the first

SAN FRANCISCO , June 24, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the closing of its initial

SAN FRANCISCO , June 19, 2019 /PRNewswire/ --  Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the pricing of its

SAN FRANCISCO, May 29, 2019 /PRNewswire/ -- Akero Therapeutics, Inc., a biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced that it has screened the first patient for its Phase 2a clinical trial

White is a Life Sciences Investment Banking Veteran San Francisco, CA – Akero Therapeutics, Inc., a biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced the appointment of Bill White as CFO and

Henderson is CFO of Turnstone Biologics San Francisco, CA – Akero Therapeutics, Inc., a biotechnology company focused on developing transformational treatments for people with non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced the appointment of Jane

President and CEO to share plans for the company's lead clinical candidate San Francisco, CA – Akero Therapeutics, Inc., a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious metabolic diseases with high unmet medical